论文部分内容阅读
目的探讨瑞替普酶联合还原型谷胱甘肽治疗急性ST段抬高型心肌梗死患者的临床疗效。方法选取2014年7月至2015年7月营口经济技术开发区第二人民医院收治的88例急性ST段抬高型心肌梗死患者作为研究对象,按随机数字表法将其分为试验组与对照组,各44例。对照组患者给予瑞替普酶,试验组患者在对照组基础上采用还原性谷胱甘肽进行治疗,比较两组患者的临床治疗效果、血液生化指标变化情况及不良反应发生情况。结果试验组患者治疗的总有效率明显高于对照组,差异有统计学意义(P<0.05);治疗后,试验组患者的肌酸激酶、心肌肌钙蛋白水平均明显低于对照组,超氧化物歧化酶水平明显高于对照组,差异均有统计学意义(均P<0.05);试验组患者的不良反应发生率明显低于对照组,差异有统计学意义(χ2=12.32,P<0.05)。结论急性ST段抬高型心肌梗死患者采用瑞替普酶联合还原型谷胱甘肽进行治疗,能取得较好临床效果,且不良反应发生率低,安全性高。
Objective To investigate the clinical efficacy of reteplase combined with reduced glutathione in patients with acute ST-segment elevation myocardial infarction. Methods A total of 88 acute ST-elevation myocardial infarction patients admitted to Second People’s Hospital of Yingkou Economic and Technological Development Zone from July 2014 to July 2015 were selected as research subjects and divided into experimental group and control group according to random number table method Group, each 44 cases. Patients in the control group were treated with reteplase. Patients in the test group were treated with reducing glutathione on the basis of the control group. The clinical effects, changes in blood biochemical parameters and incidence of adverse reactions were compared between the two groups. Results The total effective rate in treatment group was significantly higher than that in control group (P <0.05). After treatment, the levels of creatine kinase and cardiac troponin in test group were significantly lower than those in control group (P <0.05). The incidence of adverse reactions in the experimental group was significantly lower than that in the control group, the difference was statistically significant (χ2 = 12.32, P < 0.05). Conclusion The treatment of acute ST-segment elevation myocardial infarction with reteplase combined with reduced glutathione, can achieve better clinical effect, and the incidence of adverse reactions is low, high safety.